ACUT
Price
$0.31
Change
-$0.04 (-11.43%)
Updated
Mar 7 closing price
Capitalization
3.29M
MOLN
Price
$4.64
Change
-$0.37 (-7.39%)
Updated
Mar 10, 02:59 PM (EDT)
Capitalization
166.95M
65 days until earnings call
Ad is loading...

ACUT vs MOLN

Header iconACUT vs MOLN Comparison
Open Charts ACUT vs MOLNBanner chart's image
Accustem Sciences
Price$0.31
Change-$0.04 (-11.43%)
Volume$5.83K
Capitalization3.29M
Molecular Partners AG
Price$4.64
Change-$0.37 (-7.39%)
Volume$213
Capitalization166.95M
ACUT vs MOLN Comparison Chart
Loading...
View a ticker or compare two or three
VS
ACUT vs. MOLN commentary
Mar 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACUT is a Hold and MOLN is a Hold.

Ad is loading...
COMPARISON
Comparison
Mar 11, 2025
Stock price -- (ACUT: $0.31 vs. MOLN: $5.01)
Brand notoriety: ACUT and MOLN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACUT: 60% vs. MOLN: 334%
Market capitalization -- ACUT: $3.29M vs. MOLN: $166.95M
ACUT [@Biotechnology] is valued at $3.29M. MOLN’s [@Biotechnology] market capitalization is $166.95M. The market cap for tickers in the [@Biotechnology] industry ranges from $383.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACUT’s FA Score shows that 1 FA rating(s) are green whileMOLN’s FA Score has 0 green FA rating(s).

  • ACUT’s FA Score: 1 green, 4 red.
  • MOLN’s FA Score: 0 green, 5 red.
According to our system of comparison, both ACUT and MOLN are a bad buy in the long-term.

Price Growth

ACUT (@Biotechnology) experienced а +10.49% price change this week, while MOLN (@Biotechnology) price change was -0.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.84%. For the same industry, the average monthly price growth was -7.68%, and the average quarterly price growth was -7.37%.

Reported Earning Dates

MOLN is expected to report earnings on May 15, 2025.

Industries' Descriptions

@Biotechnology (+0.84% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

FUNDAMENTALS
Fundamentals
MOLN($167M) has a higher market cap than ACUT($3.29M). MOLN YTD gains are higher at: 5.518 vs. ACUT (-30.698). ACUT has higher annual earnings (EBITDA): -1.38M vs. MOLN (-60.16M). MOLN has more cash in the bank: 144M vs. ACUT (37.1K). ACUT has less debt than MOLN: ACUT (57.6K) vs MOLN (2.75M). MOLN has higher revenues than ACUT: MOLN (6M) vs ACUT (0).
ACUTMOLNACUT / MOLN
Capitalization3.29M167M2%
EBITDA-1.38M-60.16M2%
Gain YTD-30.6985.518-556%
P/E RatioN/AN/A-
Revenue06M-
Total Cash37.1K144M0%
Total Debt57.6K2.75M2%
TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ANTGX9.330.11
+1.19%
American Century Non-US Intrs Val G
RIEAX12.200.12
+0.99%
RBC International Equity A
KTCIX43.870.31
+0.71%
DWS Science and Technology Inst
FKMCX40.620.08
+0.20%
Fidelity Mid-Cap Stock K
MIEGX10.440.01
+0.10%
BNY Mellon Emerging Markets Inv

ACUT and

Correlation & Price change

A.I.dvisor tells us that ACUT and KMSTF have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ACUT and KMSTF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACUT
1D Price
Change %
ACUT100%
-11.04%
KMSTF - ACUT
28%
Poorly correlated
N/A
MOLN - ACUT
21%
Poorly correlated
+2.24%
PHGE - ACUT
20%
Poorly correlated
-4.97%
TELIF - ACUT
11%
Poorly correlated
-0.79%
BLTE - ACUT
11%
Poorly correlated
+3.49%
More

MOLN and

Correlation & Price change

A.I.dvisor indicates that over the last year, MOLN has been loosely correlated with SLDB. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if MOLN jumps, then SLDB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MOLN
1D Price
Change %
MOLN100%
+2.24%
SLDB - MOLN
36%
Loosely correlated
-1.45%
RCKT - MOLN
33%
Poorly correlated
-2.45%
ATRA - MOLN
31%
Poorly correlated
+1.47%
RAPT - MOLN
30%
Poorly correlated
+0.89%
AXON - MOLN
29%
Poorly correlated
+5.43%
More